Myomo Stock News

BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the three months and fiscal year ended December 31, 2021 on March 9, 2022 after the market close. The Company will host a conference call the same day, Wednesday, March 9, 2022 at 4:30 p.m. ET with prepared re

Myomo Inc. (MYO) shares closed this week 20.7% higher than it did at the end of last week. The stock is currently up 22.7% year-to-date, down 6.7% over the past 12 months, and down 96.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.7%. Trading Activity Shares traded as high as $8.79 and as low as $6.93 this week.Shares closed 54.5% below its 52-week high and 26.5% above its 52-week low.Trading volume this week was 28.8% lower than the 10-day average and 2.6% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Industrials industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -355.8% The company's stock price performance over the past 12 months lags the peer average by -100.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Myomo Inc. with ticker code (MYO) have now 5 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The range between the high target price and low target price is between 34 and 14.5 calculating the average target price we see 21.5. Now with the previous closing price of 8.2 this would indicate that there is a potential upside of 162.2%. The 50 day moving average now sits at 10.24 and the 200 day moving average is 10.52. The company has a market capitalisation of $53m. You can visit the company''s website by visiting: https://www.myomo.com [stock_market_widget type="chart" symbol="MYO" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Myomo, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient''s weak or paralyzed arm to enable and improve functional activities of daily living.

Myomo has a great deal of similarities in business strategy to its technological & industry peers in terms of markets, joint ventures, and insurance reimbursements. However, its cash position is much

Zacks Investment Research upgraded shares of Myomo (NYSEAMERICAN:MYO) from a hold rating to a buy rating in a report released on Tuesday morning, Zacks.com reports. They currently have $11.00 target price on the stock. According to Zacks, Myomo, Inc. is a commercial stage medical robotics company. It offers expanded mobility which suffering from neurological disorders []

Zacks Investment Research upgraded shares of Myomo (NYSEAMERICAN:MYO) from a hold rating to a buy rating in a research note released on Tuesday, Zacks.com reports. They currently have $11.00 price target on the stock. According to Zacks, Myomo, Inc. is a commercial stage medical robotics company. It offers expanded mobility which suffering from neurological disorders []

Myomo (NYSEAMERICAN:MYO) was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, Myomo, Inc. is a commercial stage medical robotics company. It offers expanded mobility which suffering from neurological disorders and upper limb paralysis. The []

Alliance Global Partners restated their buy rating on shares of Myomo (NYSEAMERICAN:MYO) in a research note released on Thursday morning, The Fly reports. The brokerage currently has a $34.00 price objective on the stock, down from their prior price objective of $36.50. Other equities analysts also recently issued reports about the company. Colliers Securities reissued []

Colliers Securities reissued their buy rating on shares of Myomo (NYSEAMERICAN:MYO) in a research report sent to investors on Thursday, TipRanks reports. They currently have a $17.00 price target on the stock. Other analysts have also issued reports about the company. Alliance Global Partners reiterated a buy rating and set a $34.00 price target (down []

Colliers Securities reaffirmed their buy rating on shares of Myomo (NYSEAMERICAN:MYO) in a research report report published on Thursday morning, TipRanks reports. Colliers Securities currently has a $17.00 price objective on the stock. Several other research firms also recently weighed in on MYO. Zacks Investment Research downgraded Myomo from a buy rating to a hold []

Myomo, Inc. (MYO) delivered earnings and revenue surprises of 23.40% and 40.06%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?